REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

15/07/2020 09:35

RNS Number : 0730T
  
GlaxoSmithKline PLC
  
15 July 2020
  
 

GlaxoSmithKline plc (the 'Company')
Transaction notification



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms E Walmsley




b)


Position/status


Chief Executive Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


788












£15.9280


784












£15.9280


631


























d)


Aggregated information
 


2,203




 
Aggregated volume Price


 
£15.9280




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Dr H Barron




b)


Position/status


Chief Scientific Officer and President, R&D




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 July 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












$40.3700


455












$40.3700


357


























d)


Aggregated information
 


812




 
Aggregated volume Price


 
$40.3700




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


New York Stock Exchange (XNYS)



 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Connor     
 




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


199












£15.9280


205












£15.9280


167


























d)


Aggregated information
 


571




 
Aggregated volume Price


 
£15.9280




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Conrad




b)


Position/status


SVP Human Resources




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


82


























d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price








e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


117


























d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price








e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


Senior Vice President and General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 July 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












$40.3700


39


























d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
 




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


New York Stock Exchange (XNYS)



 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


87












£15.9280


86












£15.9280


61


























d)


Aggregated information
 


234




 
Aggregated volume Price


 
£15.9280




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms S Jackson




b)


Position/status


SVP, Global Communications & CEO Office




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


49


























d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
£15.9280




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr I Mackay




b)


Position/status


Chief Financial Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


426


























d)


Aggregated information
 


N/A (single transaction)




 
Aggregated volume Price


 
£15.9280




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 July 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












$40.3700


76












$40.3700


81












$40.3700


65












































d)


Aggregated information
 


222




 
Aggregated volume Price


 
$40.3700




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


New York Stock Exchange (XNYS)



 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


158












£15.9280


191












£15.9280


219


























d)


Aggregated information
 


568




 
Aggregated volume Price


 
£15.9280




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


162












£15.9280


194












£15.9280


140


























d)


Aggregated information
 


496




 
Aggregated volume Price


 
£15.9280




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


99












£15.9280


70


























d)


Aggregated information
 


169




 
Aggregated volume Price


 
£15.9280




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms K Terrell




b)


Position/status


Chief Digital & Technology Officer




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs') 
ISIN: US37733W1053
 




b)


Nature of the transaction


Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 July 2020 on ADSs held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












$40.3700


27












$40.3700


97












$40.3700


66


























d)


Aggregated information
 


190




 
Aggregated volume Price


 
$40.3700




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


New York Stock Exchange (XNYS)



 
 
 
 



1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 July 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)












£15.9280


109












£15.9280


113












£15.9280


80


























d)


Aggregated information
 
 


302




Aggregated volume Price


£15.9280




e)


Date of the transaction


2020-07-13




f)


Place of the transaction
 


London Stock Exchange (XLON)



 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
DSHVELBFBDLLBBK